Want to see IL:PPBT full AI Analyst Report?
PPBT Stock Chart & Stats
1.00
0.00(0.00%)
At close: 4:00 PM EDT
1.00
0.00(0.00%)
Day’s Range― - ―
52-Week Range1.00 - 2.20
Previous CloseN/A
Volume1.00
Average Volume (3M)21.13K
Market Cap
₪32.42M
Enterprise Value3.76
Total Cash (Recent Filing)₪6.11M
Total Debt (Recent Filing)₪134.00K
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.96%
Share Statistics
EPS (TTM)-0.31
Shares Outstanding3,241,963,400
10 Day Avg. Volume49,200
30 Day Avg. Volume21,133
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits interest and repayment pressure, giving Purple Biotech greater financial flexibility than a similarly loss-making company funded heavily with debt.
Differentiated IM1240 Preclinical ProfileActivity in treatment-resistant models and dependence on both functional arms support a differentiated immunotherapy mechanism, potentially improving the program's ability to address difficult oncology settings if clinical results translate.
Improved Candidate Pharmacology And Safety SignalsLonger exposure, slower clearance, and reduced cytokine-release signals in non-human primates could support less frequent dosing and a wider development window, addressing important practical and safety hurdles for T-cell engagers.
Bears Say
No Demonstrated Revenue BaseThe absence of meaningful product revenue leaves the company dependent on future licensing, collaboration payments, milestones, or financing rather than self-sustaining commercial cash inflows.
Persistent Operating LossesLarge and widening losses indicate that development spending is not yet supported by operating income. Continued investment will be necessary before profitability, increasing execution risk across the clinical pipeline.
Ongoing Cash Burn And Funding DependenceNegative operating and free cash flow means losses are consuming cash, while substantial equity erosion points to reliance on external capital. Future funding needs could constrain development or dilute existing shareholders.
Purple Biotech News
PPBT FAQ
What was Purple Biotech Ltd.’s price range in the past 12 months?
Purple Biotech Ltd. lowest stock price was 1.00 and its highest was 2.20 in the past 12 months.
What is Purple Biotech Ltd.’s market cap?
Purple Biotech Ltd.’s market cap is ₪32.42M.
When is Purple Biotech Ltd.’s upcoming earnings report date?
Purple Biotech Ltd.’s upcoming earnings report date is Nov 13, 2026 which is in 67 days.
How were Purple Biotech Ltd.’s earnings last quarter?
Purple Biotech Ltd. released its earnings results on Aug 07, 2026. The company reported 0.1 earnings per share for the quarter.
Is Purple Biotech Ltd. overvalued?
According to Wall Street analysts Purple Biotech Ltd.’s price is currently Overvalued.
Does Purple Biotech Ltd. pay dividends?
Purple Biotech Ltd. pays a Notavailable dividend of 249.549 which represents an annual dividend yield of 0.96%. See more information on Purple Biotech Ltd. dividends here
What is Purple Biotech Ltd.’s EPS estimate?
Purple Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Purple Biotech Ltd. have?
Purple Biotech Ltd. has 3,241,963,400 shares outstanding.
What happened to Purple Biotech Ltd.’s price movement after its last earnings report?
Purple Biotech Ltd. reported an EPS of 0.1 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Purple Biotech Ltd.?
Currently, no hedge funds are holding shares in IL:PPBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.